Wall Street analysts expect that United Therapeutics Co. (NASDAQ:UTHR) will post earnings of $2.40 per share for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for United Therapeutics’ earnings, with estimates ranging from $1.94 to $2.67. United Therapeutics reported earnings per share of $4.36 during the same quarter last year, which suggests a negative year over year growth rate of 45%. The firm is expected to report its next quarterly earnings results on Wednesday, August 7th.
According to Zacks, analysts expect that United Therapeutics will report full-year earnings of ($5.03) per share for the current year, with EPS estimates ranging from ($7.70) to ($2.89). For the next financial year, analysts forecast that the firm will post earnings of $9.01 per share, with EPS estimates ranging from $7.68 to $10.51. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow United Therapeutics.
United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported ($11.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.64 by ($13.96). United Therapeutics had a negative return on equity of 5.78% and a negative net margin of 9.36%. The firm had revenue of $362.70 million during the quarter, compared to analysts’ expectations of $335.72 million. During the same quarter in the previous year, the company posted $3.76 earnings per share. United Therapeutics’s revenue for the quarter was down 6.8% compared to the same quarter last year.
A number of research firms have recently issued reports on UTHR. Barclays cut their price objective on United Therapeutics from $100.00 to $95.00 and set an “underweight” rating for the company in a report on Friday, March 1st. BidaskClub upgraded United Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, March 1st. LADENBURG THALM/SH SH set a $124.00 price objective on United Therapeutics and gave the stock a “hold” rating in a report on Thursday, February 28th. Cowen reiterated a “hold” rating and issued a $109.00 price objective on shares of United Therapeutics in a report on Wednesday, February 27th. Finally, Oppenheimer reiterated a “buy” rating on shares of United Therapeutics in a report on Tuesday, March 19th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the stock. United Therapeutics presently has a consensus rating of “Hold” and an average price target of $132.89.
In related news, Director Christopher Patusky sold 3,370 shares of the stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $110.75, for a total transaction of $373,227.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 8.20% of the company’s stock.
A number of hedge funds have recently modified their holdings of UTHR. Fort L.P. purchased a new stake in United Therapeutics during the 1st quarter valued at about $25,000. Captrust Financial Advisors lifted its holdings in United Therapeutics by 384.9% in the 4th quarter. Captrust Financial Advisors now owns 257 shares of the biotechnology company’s stock worth $28,000 after buying an additional 204 shares during the period. Rockefeller Capital Management L.P. purchased a new stake in United Therapeutics in the 1st quarter worth approximately $29,000. Oregon Public Employees Retirement Fund lifted its holdings in United Therapeutics by 10,537.5% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 3,551,229 shares of the biotechnology company’s stock worth $33,000 after buying an additional 3,517,845 shares during the period. Finally, First Mercantile Trust Co. lifted its holdings in United Therapeutics by 47.8% in the 4th quarter. First Mercantile Trust Co. now owns 340 shares of the biotechnology company’s stock worth $37,000 after buying an additional 110 shares during the period. Institutional investors own 97.29% of the company’s stock.
Shares of UTHR traded up $0.38 during midday trading on Friday, reaching $89.71. The stock had a trading volume of 14,373 shares, compared to its average volume of 436,571. United Therapeutics has a 12-month low of $88.25 and a 12-month high of $130.00. The company has a current ratio of 7.19, a quick ratio of 6.84 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $3.91 billion, a P/E ratio of 6.68 and a beta of 1.01.
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.
Recommended Story: What is a balanced fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.